Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids

Carcinogenesis

Volumn 28, Issue 9, 2007, Pages 1991-1995

  Nowak, Johannes ^a,b   Weylandt, Karsten H ^b   Habbel, Piet ^a,b   Wang, Jingdong ^a   Dignass, Axel ^b   Glickman, Jonathan N ^c   Kang, Jing X ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; OMEGA 3 FATTY ACID; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; COLITIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; CAENORHABDITIS ELEGANS PROTEINS; COLITIS; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA, NEOPLASM; FATTY ACID DESATURASES; FATTY ACIDS, OMEGA-3; GENETIC MARKERS; HUMANS; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; TUMOR SUPPRESSOR PROTEINS; UNITED STATES;

EID: 34848875143     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm166     Document Type: Article

References (30)

1. Ries,L.A.G. et al. (eds). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/.
2. Arber,N. et al. (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med., 355, 885-895.
3. Baron, J.A. et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med., 348, 891-899.
4. Bertagnolli,M.M. et al. (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med., 355, 873-884.
5. Janne,P.A. et al. (2000) Chemoprevention of colorectal cancer. N. Engl. J. Med., 342, 1960-1968.
6. Greten,F.R. et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118, 285-296.
7. Endres,S. et al. (1989) The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N. Engl. J. Med., 320, 265-271.
8. Belluzzi,A. et al. (1996) Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N. Engl. J. Med., 334, 1557-1560.
9. Arita,M. et al. (2005) Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med., 201, 713-722.
10. Hudert,C.A. et al. (2006) Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc. Natl Acad. Sci. USA, 103, 11276-11281.
11. Serhan,C.N. et al. (2005) Resolution of inflammation: The beginning programs the end. Nat. Immunol., 6, 1191-1197.
12. Reddy,B.S. et al. (1991) Effect of diets high in omega-3 and omega-6 fatty acids on initiation and postinitiation stages of colon carcinogenis. Cancer Res., 51, 487-491.
13. Reddy,B.S. et al. (1988) Effect of different levels of omega-3 and omega-6 fatty acids on azoxymethane-induced colon carcinogenesis in F344 rats. Cancer Res., 48, 6642-6647.
14. Kang,J.X. et al. (2004) Transgenic mice: Fat-1 mice convert n-6 to n-3 fatty acids. Nature, 427, 504.
15. Kang,J.X. et al. (2005) A simplified method for analysis of polyunsaturated fatty acids. BMC Biochem., 6, 5.
16. Suzuki,R. et al. (2004) Sequential observations on the occurrence of preneoplastic and neoplastic lesions in mouse colon treated with azoxymethane and dextran sodium sulfate, Cancer Sci., 95, 721-727.
17. Suzuki,R. et al. (2005) Dose-dependent promoting effect of dextran sodium sulfate on mouse colon carcinogenesis initiated with azoxymethane. Histol. Histopathol., 20, 483-492.
18. Suzuki,R. et al. (2006) Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis, 27, 162-169.
19. Cooper,H.S. et al. (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest., 69 238-249.
20. Okayasu,I. et al. (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology, 98, 694-702.
21. Schmocker,C. et al. (2007) Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Hepatology, 45, 864-869.
22. Bhattacharya,A. et al. (2006) Inhibition of inflammatory response in transgenic fat-1 mice on a calorie-restricted diet. Biochem. Biophys. Res. Commun., 349, 925-930.
23. Rao,C.V. et al. (1999) Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis, 20, 641-644.
24. Rao,C.V. et al. (2002) Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res., 62, 165-170.
25. Rao,C.V. (2004) Nitric oxide signaling in colon cancer chemoprevention. Mutat. Res., 555, 107-119.
26. Rao,C.V. et al. (2006) Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: Effects on molecular targets. Mol. Cancer Ther., 5, 1530-1538.
27. Tang,B. et al. (1998) Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat. Med. 4, 802-807.
28. Cao,Y. et al. (2006) TGF-beta inhibits Akt-induced transformation in intestinal epithelial cells. Surgery, 140, 322-329.
29. Wang,C. et al. (2006) n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: A systematic review. Am. J. Clin. Nutr., 84, 5-17.
30. Chapkin,R.S. et al. (2007) Colon cancer, fatty acids and anti-inflammatory compounds. Curr. Opin. Gastroenterol., 23, 48-54.